Embedded Files
AstraZeneca is expanding its AI-powered target discovery, partnering with Immunai in an $85M deal to develop novel therapeutics for IBD using single-cell immune-mapping technology.
Why It Matters To Oncology
▪ Expands AI-driven immune-target discovery beyond oncology, leveraging tech that has already informed cancer drug development and biomarker identification.
▪ Validates cross-disease applications of single-cell multi-omics and AI models pioneered in oncology clinical trials.
The Financials
▪ Immunai receives upfront and milestone payments up to $85M.
▪ Follows AstraZenecas $18M commitment in 2023 for oncology-focused immunomics; adds to a growing portfolio of AI-enabled R&D deals (e.g., $555M with Algen Biotechnologies).
What They're Saying
▪ Immunai CEO Noam Solomon: “By modelling the immune system with high-resolution single-cell data and AI, were not only finding new targets, were beginning to understand why they matter.”
What's Next
▪ AstraZeneca will lead development and commercialization of IBD therapies targeting Immunais discovery.
▪ Watch for further AI collaborations across immunology and oncology, including ADC virtualisation and next-gen sequencing projects.
Page updated
Report abuse